Estrogen and Progesterone Receptors in Human Colorectal Tumour Cells (Study of 70 Cases)

1988 ◽  
Vol 3 (1) ◽  
pp. 41-48 ◽  
Author(s):  
G. Bracali ◽  
A.M. Caracino ◽  
F. Rossodivita ◽  
C. Bianchi ◽  
M.G. Loli ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Estrogen Receptor ◽  
Progesterone Receptor ◽  
Estrogen Receptors ◽  
Progesterone Receptors ◽  
Human Colorectal Cancer ◽  
Estrogen And Progesterone Receptors ◽  
Colorectal Tumour ◽  
Estrogen Receptor Positive ◽  
Cytochemical Technique

Estrogen and progesterone receptors were studied in 70 cases of human colorectal cancer by a cytochemical technique. 28.5% of the cases were estrogen-receptor positive and 42.8% progesterone-receptor positive. There was no difference between the sexes for estrogen receptors but the women had more tumours with progesterone receptors than men. The presence of receptors is unrelated to the differentiation of the tumour. More colon tumours were positive than those of the sigma and rectum. The concentration of cells with receptors in positive cancer cases tended to be low or medium-low.

scholarly journals Association of genetic polymorphisms of estrogen and progesterone receptors and endometriosis: Meta-analysis

2019 ◽  
Vol 11 (1) ◽  
pp. 25-36
Author(s):  
Priscila Prais Carneiro ◽  
Bruna Vicente de Oliveira ◽  
Antonio Marcio Teodoro Cordeiro Silva
Keyword(s):  
Estrogen Receptor ◽  
Progesterone Receptor ◽  
Estrogen Receptor Alpha ◽  
Meta Analysis ◽  
Estrogen Receptor Beta ◽  
Progesterone Receptors ◽  
Estrogen And Progesterone Receptors ◽  
Receptor Alpha ◽  
Pubmed Database ◽  
Receptor Beta

Purpose: To investigate the association between polymorphisms in the genes of estrogen receptor alpha, estrogen receptor beta, and progesterone receptor and the genesis of endometriosis. Methods: Systematic review and meta-analysis of articles published fully in the PubMed database, in Portuguese, English, or Spanish, from 2006 to 2017, using the descriptors: “endometriosis,” “polymorphism,” “ESR1,” “ESR2,” “PROGINS,” “rs9340799,” “rs4986938,” and “rs1042838.” Results: A total of 20 studies were included based on the criterion of search for susceptibility to endometriosis related to polymorphisms of estrogen receptor alpha, estrogen receptor beta, and progesterone receptor genes. Analysis of all polymorphisms found no association with endometriosis. Conclusion: This meta-analysis showed that estrogen receptor alpha, estrogen receptor beta, and progesterone receptor polymorphisms are not related to susceptibility to endometriosis. However, such results may be able to provide more detailed interpretations of how they influence the pathogenesis of endometriosis.

scholarly journals Features of the gene polymorphism of estrogen and progesterone receptors in women with uterine leiomyoma

2012 ◽  
Vol 61 (3) ◽  
pp. 109-114
Author(s):  
Natalya Sergeevna Osinovskaya ◽  
Tatyana Eduardovna Ivaschenko ◽  
Lyailya Kharryasovna Dzhemlikhanova ◽  
Vladislav Sergeevich Baranov ◽  
Antonina Nicolaevna Tkachenko ◽  
...  
Keyword(s):  
Estrogen Receptor ◽  
Comparative Analysis ◽  
Progesterone Receptor ◽  
Gene Polymorphism ◽  
Uterine Leiomyoma ◽  
Progesterone Receptors ◽  
Female Reproductive System ◽  
Estrogen And Progesterone Receptors ◽  
Polymorphic Variants ◽  
Female Genital

Uterine Leiomyoma (Leiomyoma) (LM) — benign and most common (incidence 20–45 %) hormone-dependent tumors of female genital organs. Comparative analysis of frequencies of polymorphic variants of genes of estrogen receptor (ERα) and progesterone receptor (PGR) in patients with LM and the population samples was conducted in this work. Also it was investigated their association with clinical manifestation of hyperplastic processes of the female reproductive system. It was founded that the development of LM are not associated with individual polymorphic variants of genes of estrogen receptor and progesterone receptor. This fact does not include their participation in the development of proliferative and hyperplastic processes of the myometrium

An immunohistochemical study of estrogen and progesterone receptors in adenocarcinoma of the endometrium and in the adjacent mucosa

1995 ◽  
Vol 5 (4) ◽  
pp. 275-281 ◽  
Author(s):  
H. Kerner ◽  
E. Sabo ◽  
M. Friedman ◽  
D. Beck ◽  
O. Samare ◽  
...  
Keyword(s):  
Estrogen Receptor ◽  
Endometrial Cancer ◽  
Progesterone Receptor ◽  
Estrogen Receptor Status ◽  
Endometrial Adenocarcinoma ◽  
Progesterone Receptors ◽  
Myometrial Invasion ◽  
Inverse Correlation ◽  
Immunohistochemical Analysis ◽  
Receptor Status

The immunoperoxidase stain for estrogen and progesterone receptor content in endometrial adenocarcinoma was correlated with the grade and stage, level of myometrial invasion, age and survival of the patients. Anti-estrogen and anti-progesteone receptor monoclonal antibodies were applied to paraffin-embedded tissue from hysterectomy specimens of 100 patients with adenocarcinoma of the endometrium. In 34 of the cases the receptors were studied in the endometrium adjacent to the tumor and compared to the nuclear receptor content in the carcinoma. There was a high inverse correlation between the estrogen receptor status and the grade of tumor (R= − 0.45,P= 0.006). The estrogen receptor measured in the endometrium near the tumor showed a negative correlation with the grade of the tumor (R= −0.42,P= 0.013). The estrogen, but not the progesterone, receptor content, was positively related to the age of the patient (P< 0.05). No significant correlation of the receptor status with the depth of myometrial invasion was found, despite the obvious interdependence between the grade and myometrial invasion. The progesterone receptor staining index appeared to be a distinct independent prognostic factor in endometrial cancer. The immunohistochemical analysis of the steroid hormone status in endometrial cancer therefore offers an alternative to the quantitative ligand-binding assay.

scholarly journals Progesterone Receptor Gene Variants in Metastatic Estrogen Receptor Positive Breast Cancer

2020 ◽  
Vol 11 (2) ◽  
pp. 63-75 ◽  
Author(s):  
Amy M. Fowler ◽  
Kelley Salem ◽  
Michael DeGrave ◽  
Irene M. Ong ◽  
Shane Rassman ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Progesterone Receptor ◽  
Receptor Gene ◽  
Gene Variants ◽  
Progesterone Receptor Gene ◽  
Estrogen Receptor Positive ◽  
Positive Breast Cancer

An immunohistochemical study with an estrogen receptor-related protein (ER-D5) in human colorectal cancer

Cancer ◽  
1992 ◽  
Vol 69 (4) ◽  
pp. 907-912 ◽  
Author(s):  
Hiroaki Takeda ◽  
Mitsunori Yamakawa ◽  
Tsuneo Takahashi ◽  
Yutaka Imai ◽  
Mokoto Ishikawa
Keyword(s):  
Colorectal Cancer ◽  
Estrogen Receptor ◽  
Immunohistochemical Study ◽  
Related Protein ◽  
Human Colorectal Cancer

Transcriptional activation of the estrogen receptor

1993 ◽  
Vol 39 (2) ◽  
pp. 341-345 ◽  
Author(s):  
L L Wei
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Estrogen Receptors ◽  
Transcriptional Activation ◽  
Breast Cancer Cells ◽  
Wild Type ◽  
Resistant Phenotype ◽  
Estrogen Receptor Positive ◽  
Almost All

Abstract Almost all breast cancer tumors progress to a hormone-resistant state. Evidence is presented that the existence of mutant estrogen receptors may explain some hormone-resistant phenotypes. Breast tumor cells bearing a mutant receptor that is constitutively active and does not bind hormone would have unregulated cell growth and thus appear to be hormone-independent. Alternatively, breast cancer cells may contain estrogen receptors that are transcriptionally inactive but when co-expressed with wild-type receptors render normal estrogen receptors inactive. These cells would be considered estrogen receptor-positive but would be hormone-resistant. The hormone-resistant phenotype could be further complicated by the finding that other nonreceptor proteins may also modulate the transcriptional activity of estrogen receptors. These findings, if substantiated in vivo, could add to the complexity of the hormone-resistant phenotype. Different strategies of treatment will need to be developed to effectively treat the various subtypes of hormone-resistant breast tumors.

Sign in / Sign up

Export Citation Format

Share Document